幽门螺旋杆菌脲酶的性质及应用现状
Properties and Application of Helicobacter pylori Urease
DOI: 10.12677/PI.2021.103018, PDF,   
作者: 卓 越, 陈建华*：中国药科大学生命科学与技术学院，江苏 南京
关键词: 幽门螺旋杆菌；脲酶；疫苗；Helicobacter pylori； Urease； Vaccine
摘要: 幽门螺旋杆菌是一种与胃癌密切相关的细菌，它利用独特的适应机制，包括脲酶的催化活性，在大部分人的胃的酸性环境中生长。靶向脲酶是药物设计和根除幽门螺旋杆菌的关键策略。本文整理了脲酶与幽门螺旋杆菌危害之间的关联性，并对幽门螺旋杆菌脲酶的性质及其在幽门螺旋杆菌感染检测及治疗中的应用的最新进展进行综述。
Abstract: Helicobacter pylori is a bacterium closely related to gastric cancer. It uses unique adaptive mechanisms, including catalytic activity of urease, to thrive in the acidic environment of the stomach of most people. Targeting urease is a key strategy for drug design and eradication of Helicobacter pylori. In this paper, the association between urease and the harm of Helicobacter pylori was summarized, and the properties of urease of Helicobacter pylori as well as its application and recent progress in the detection and treatment of Helicobacter pylori infection were reviewed.
文章引用：卓越, 陈建华. 幽门螺旋杆菌脲酶的性质及应用现状[J]. 药物资讯, 2021, 10(3): 138-141. https://doi.org/10.12677/PI.2021.103018

参考文献

[1] Devi, T.B., Devadas, K., George, M., Gandhimathi, A., Chouhan, D., Retnakumar, R.J., et al. (2021) Low Bifidobacte-rium Abundance in the Lower Gut Microbiota Is Associated with Helicobacter pylori-Related Gastric Ulcer and Gastric Cancer. Front Microbiol, 12, Article ID: 631140. [Google Scholar] [CrossRef] [PubMed]
[2] Isomoto, H., Moss, J. and Hirayama, T. (2010) Pleiotropic Actions of Helicobacter Pylori Vacuolating Cytotoxin, VacA. The Tohoku Journal of Experimental Medicine, 220, 3-14. [Google Scholar] [CrossRef] [PubMed]
[3] Hatakeyama, M. (2014) Helicobacter pylori CagA and Gastric Cancer: A Paradigm for Hit-and-Run Carcinogenesis. Cell Host Microbe, 15, 306-316. [Google Scholar] [CrossRef] [PubMed]
[4] Tsuda, M., Karita, M., Morshed, M.G., Okita, K. and Nakazawa, T. (1994) A Urease-Negative Mutant of Helicobacter pylori Constructed by Allelic Exchange Mutagenesis Lacks the Ability to Colonize the Nude Mouse Stomach. Infection and Immunity, 62, 3586-3589. [Google Scholar] [CrossRef] 
[5] 谷贵章, 宋达峰, 顾青. 幽门螺杆菌尿素酶的分子特性[J]. 药物生物技术, 2007, 14(4): 291-296.
[6] Montecucco, C., Papini, E., de Bernard, M. and Zoratti, M. (1999) Molecular and Cellular Activities of Helicobacter pylori Pathogenic Factors. FEBS Letters, 452, 16-21. [Google Scholar] [CrossRef] 
[7] 盛涛, 张建中. 幽门螺杆菌尿素酶研究现状[J]. 世界华人消化杂志, 1999, 7(10): 881-884.
[8] Kappaun, K., Piovesan, A.R., Carlini, C.R. and Ligabue-Braun, R. (2018) Ureases: Historical Aspects, Catalytic, and Non-Catalytic Properties—A Review. Journal of Advanced Research, 13, 3-17. [Google Scholar] [CrossRef] [PubMed]
[9] Krajewska, B. (2009) Ureases I. Functional, Catalytic and Kinetic Properties: A Review. Journal of Molecular Catalysis B: Enzymatic, 59, 9-21. [Google Scholar] [CrossRef] 
[10] Hu, L.T. (1992) Helicobacter pylori Urease: Purification, Mo-lecular Cloning, and Enzymatic Activation in Escherichia coli. Microbiology Ph.D. Thesis, University of Maryland, Bal-timore.
[11] Cussac, V., Ferrero, R.L. and Labigne, A. (1992) Expression of Helicobacter pylori Urease Genes in Escherichia coli Grown under Nitrogen-Limiting Conditions. Journal of Bacteriology, 174, 2466-2473. [Google Scholar] [CrossRef] [PubMed]
[12] Pajares-García, J.M. (1998) Diagnosis of Helicobacter pylori: Invasive Methods. Italian Journal of Gastroenterology and Hepatology, 3, S320-S323.
[13] Dechant, F.X., Dechant, R., Kandulski, A., Selgrad, M., Weber, F., Reischl, U., Wilczek, W., Mueller, M. and Weigand, K. (2020) Accuracy of Dif-ferent Rapid Urease Tests in Comparison with Histopathology in Patients with Endoscopic Signs of Gastritis. Digestion, 101, 184-190. [Google Scholar] [CrossRef] [PubMed]
[14] 曾妙, 杨三三, 李雪诺, 陈安海. 幽门螺旋杆菌的检测方法研究现状[J]. 海南医学, 2020, 31(6): 784-788.
[15] Sankararaman, S. and Moosavi, L. (2021) Urea Breath Test. StatPearls Publishing, Treasure Island.
[16] 崔璨璨, 李长锋, 张斌. 幽门螺旋杆菌感染治疗方案的研究现状和进展[J]. 吉林大学学报(医学版), 2017, 43(6): 1287-1290.
[17] Liu, M., Zhong, Y., Chen, J., Liu, Y., Tang, C., Wang, X., et al. (2020) Oral Immunization of Mice with a Multivalent Therapeutic Subunit Vaccine Protects against Helicobac-ter pylori Infection. Vaccine, 38, 3031-3041. [Google Scholar] [CrossRef] [PubMed]
[18] Xie, W., Zhao, W., Zou, Z., Kong, L. and Yang, L. (2021) Oral Multivalent Epitope Vaccine, Based on UreB, HpaA, CAT, and LTB, for Prevention and Treatment of Helicobacter py-lori Infection in C57BL/6 Mice. Helicobacter, 12, Article ID: e12807. [Google Scholar] [CrossRef] [PubMed]
[19] Zeng, M., Mao, X.H., Li, J.X., Tong, W.D., Wang, B., Zhang, Y.J., Guo, G., et al. (2015) Efficacy, Safety, and Immunogenic-ity of an Oral Recombinant Helicobacter pylori Vaccine in Children in China: A Randomised, Double-Blind, Place-bo-Controlled, Phase 3 Trial. Lancet, 386, 1457-1464. [Google Scholar] [CrossRef] 
[20] Blanchard, T.G. and Czinn, SJ. (2017) Identification of Hel-icobacter pylori and the Evolution of an Efficacious Childhood Vaccine to Protect against Gastritis and Peptic Ulcer Dis-ease. Pediatric Research, 81, 170-176. [Google Scholar] [CrossRef] [PubMed]